Peptris' $7.7M Series A bets on AI to compress drug discovery economics

Peptris closed a $7.7M Series A in February 2026, co-led by IAN Alpha Fund and Speciale Invest, with participation from Tenacity Ventures and BYT Ventures. The startup operates a proprietary AI platform that applies unsupervised learning and generative AI to design optimized molecules for drug development. Founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni and Amit Mahajan, Peptris claims its platform has been deployed to discover novel chemical entities, repurpose approved drugs, and rescue molecules that reached clinical safety thresholds before being shelved.

The round positions Peptris to expand its pipeline over the next two years, launching new Novel Chemical Entity programmes alongside drug repurposing and rescue initiatives. The company plans to hire across biology, chemistry, data science and AI functions, and establish dedicated business development units in the US and Europe. Peptris operates as a virtual entity, outsourcing wet lab work to contract research organizations and biotech partners while capturing revenue through licensing deals, milestone payments and royalties. This licensing-and-milestone model distinguishes it from early-stage biotech that bears full R&D risk in-house; instead, Peptris’ economics depend on pharma and biotech partners adopting its discoveries and advancing them clinically.

The round addresses a persistent structural tension in drug discovery: preclinical development consumes disproportionate time and capital relative to its probability of clinical success. The signal from investors suggests confidence that AI-augmented molecule design can compress this phase and improve hit rates. An open question is whether Peptris’ virtual model—relying on outsourced wet lab validation and pharma partnerships for advancement—can scale discovery velocity fast enough to justify venture returns. Worth watching whether the company’s pipeline translates to material licensing deals or milestone payments within the next 18–24 months, or whether revenue models in AI-assisted drug discovery prove slower to monetize than the funding thesis anticipates.